Logo image of HYPD

HYPERION DEFI INC (HYPD) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:HYPD - US30234E2037 - Common Stock

3.04 USD
+0.12 (+4.11%)
Last: 1/23/2026, 5:20:02 PM
3.1 USD
+0.06 (+1.97%)
After Hours: 1/23/2026, 5:20:02 PM

HYPD Key Statistics, Chart & Performance

Key Statistics
Market Cap24.62M
Revenue(TTM)57.30K
Net Income(TTM)-49.82M
Shares8.10M
Float5.72M
52 Week HighN/A
52 Week LowN/A
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-50.93
PEN/A
Fwd PEN/A
Earnings (Next)04-13
IPO2018-01-25
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
HYPD short term performance overview.The bars show the price performance of HYPD in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60

HYPD long term performance overview.The bars show the price performance of HYPD in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of HYPD is 3.04 USD. In the past month the price decreased by -18.93%.

HYPERION DEFI INC / HYPD Daily stock chart

HYPD Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

HYPD Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to HYPD. Both the profitability and financial health of HYPD have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

HYPD Financial Highlights

Over the last trailing twelve months HYPD reported a non-GAAP Earnings per Share(EPS) of -50.93. The EPS increased by 4.98% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -60.17%
ROE -70.41%
Debt/Equity 0.11
Chartmill High Growth Momentum
EPS Q2Q%102.22%
Sales Q2Q%18806.25%
EPS 1Y (TTM)4.98%
Revenue 1Y (TTM)1407.89%

HYPD Forecast & Estimates

8 analysts have analysed HYPD and the average price target is 5.99 USD. This implies a price increase of 97.12% is expected in the next year compared to the current price of 3.04.

For the next year, analysts expect an EPS growth of 33.51% and a revenue growth -7.67% for HYPD


Analysts
Analysts82.5
Price Target5.99 (97.04%)
EPS Next Y33.51%
Revenue Next Year-7.67%

HYPD Ownership

Ownership
Inst Owners9%
Ins Owners26.18%
Short Float %32.55%
Short Ratio6.35

About HYPD

Company Profile

HYPD logo image Hyperion DeFi, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2018-01-25. The firm is focused on providing simplified access to the Hyperliquid ecosystem. The company is also developing its proprietary Optejet User Filled Device (UFD) that is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products. The Optejet is useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may result in higher treatment compliance and better outcomes for patients and providers. The company has launched its cryptocurrency treasury reserve, which is native to the decentralized digital asset exchange and Layer-1 blockchain, Hyperliquid. Hyperliquid is a layer one blockchain (L1) written and optimized from first principles.

Company Info

HYPERION DEFI INC

295 Madison Avenue, Suite 2400

New York City NEW YORK US

Employees: 13

HYPD Company Website

HYPD Investor Relations

Phone: 18333936684

HYPERION DEFI INC / HYPD FAQ

What does HYPD do?

Hyperion DeFi, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2018-01-25. The firm is focused on providing simplified access to the Hyperliquid ecosystem. The company is also developing its proprietary Optejet User Filled Device (UFD) that is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products. The Optejet is useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may result in higher treatment compliance and better outcomes for patients and providers. The company has launched its cryptocurrency treasury reserve, which is native to the decentralized digital asset exchange and Layer-1 blockchain, Hyperliquid. Hyperliquid is a layer one blockchain (L1) written and optimized from first principles.


Can you provide the latest stock price for HYPERION DEFI INC?

The current stock price of HYPD is 3.04 USD. The price increased by 4.11% in the last trading session.


What is the dividend status of HYPERION DEFI INC?

HYPD does not pay a dividend.


What is the ChartMill rating of HYPERION DEFI INC stock?

HYPD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Is HYPERION DEFI INC (HYPD) stock a good buy?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on HYPD.


What is the market capitalization of HYPD stock?

HYPERION DEFI INC (HYPD) has a market capitalization of 24.62M USD. This makes HYPD a Nano Cap stock.


Can you provide the ownership details for HYPD stock?

You can find the ownership structure of HYPERION DEFI INC (HYPD) on the Ownership tab.